Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Melanoma 16Triple Negative Breast Neoplasms 13Colorectal Neoplasms 11Neoplasms 9Neoplasm Metastasis 9Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Carcinoma, Renal Cell 7Stomach Neoplasms 6Lymphoma 6Uterine Cervical Neoplasms 5Ovarian Neoplasms 5Lung Neoplasms 4Liver Neoplasms 4Head and Neck Neoplasms 4Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Endometrial Neoplasms 4Breast Neoplasms 4Small Cell Lung Carcinoma 3Sarcoma 3Nasopharyngeal Carcinoma 3Colonic Neoplasms 3Carcinoma, Hepatocellular 3Advanced Solid Tumor 3Solid Tumors 2Solid Tumor, Adult 2Recurrence 2Rectal Neoplasms 2

Interventions

Imatinib Mesylate 5ruxolitinib 4ponatinib 4nilotinib 4Azacitidine 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2spartalizumab 1sonidegib 1simtuzumab 1sabatolimab 1bosutinib 1Zoledronic Acid 1SCIO-469 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Denosumab 1Decitabine 1CPI-0610 1BID protein, human 14-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bone Marrow Diseases × spartalizumab × Clear all
NCT03066648 2025-05-18

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Novartis

Phase 1 Completed
241 enrolled
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡